Antonin de Fougerolles

Antonin (Tony) de Fougerolles has 25 years of biotech R&D experience in building out drug pipelines and he has played a key role in developing and successfully advancing three new drug modalities to the market (mRNA, RNAi, single domain antibodies) and in helping build several multi-billion dollar companies from early start-up stage (fewer than ten employees), including Moderna and Alnylam.

Tony is the CEO of Evox Therapeutics, where he is developing exosome therapeutics, thus creating enabling genetic medicines that can be used to their fullest potential. He has held senior R&D positions at Ablynx (CSO), Moderna (Founding CSO), Tolerx (CSO), and Alnylam (VP Research). He is the inventor of the foundational work around the mRNA chemistry (1-methyl pseudouridine) and lipid nanoparticle formulations that are used in both the approved Moderna and Pfizer/BioNTech covid-19 vaccines and broadly across the industry (see IP section of this profile for details on three key patents out of over fifty Moderna patents where Tony is a named inventor).